NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Aug. 28, 2015--
Lantheus
Holdings, Inc. (the “Company”) (NASDAQ: LNTH), parent company of
Lantheus Medical Imaging, Inc. (“LMI”), a global leader in developing,
manufacturing, selling and distributing innovative diagnostic imaging
agents and products, today announced the appointment of Mary Anne Heino
as the new President and Chief Executive Officer and a director of the
Company. Ms. Heino replaces Jeff Bailey, who has served as President and
Chief Executive Officer and a director of the Company since January 2013
and is retiring from operational management to focus on Board positions.
Mr. Bailey will continue with the Company on a consulting basis until
March 31, 2016 and will work with Ms. Heino to ensure a smooth
transition.
Ms. Heino, age 55, brings to the Company more than 25 years of diverse
pharmaceutical industry experience. Joining the Company in April 2013 as
Chief Commercial Officer, Ms. Heino was promoted to Chief Operating
Officer in March 2015.
“Since Mary Anne has joined the Company, she has demonstrated impressive
leadership and a deep understanding of our business and industry, first
heading our global commercial team and then adding our sophisticated
manufacturing and global sourcing operations to her responsibilities,”
said Brian Markison, Chairman of the Board of the Company. “Mary Anne’s
strong commercial and operational skills and strategic vision will be a
great asset for us as we focus on continued growth of the Company.”
Prior to joining the Company, Ms. Heino led Angelini Labopharm LLC and
Labopharm USA in the roles of President and Senior Vice President of
World Wide Sales and Marketing. Before that, Ms. Heino served in
numerous capacities at Centocor, Inc., a Johnson & Johnson Company,
including Vice President Strategic Planning and Competitive
Intelligence, Vice President Sales, Executive Director Customer
Relationship Management and Senior Director Immunology Marketing.
Ms. Heino began her professional career with Janssen Pharmaceutica as a
Sales Representative in June 1989 and worked her way up to the role of
Field Sales Director in 1999. Ms. Heino received her Master’s in
Business Administration from the Stern School of Business at New York
University. She earned a Bachelor’s of Science in Nursing from the City
University of New York and a Bachelor’s of Science in Biology from the
State University of New York at Stony Brook.
Speaking about Ms. Heino, Mr. Bailey said, “I have had the pleasure of
working with Mary Anne for many years at both Lantheus and Johnson &
Johnson. She is an excellent leader with a proven track record, and I am
proud that she will be taking the reins from here.”
Speaking about Mr. Bailey, Mr. Markison said, “I have now worked with
Jeff Bailey on three separate occasions, and he has again done a great
job, this time as President and CEO of the Company since January 2013.
During his tenure, Jeff has helped diversify our supply chain, enhance
operational efficiencies, grow both revenues and margins, and deleverage
our balance sheet. On behalf of the Board and everyone at the Company, I
thank Jeff for all he has done and wish him all the best in his new
endeavors."
About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.
Lantheus Holdings, Inc. is the parent company of Lantheus Medical
Imaging, Inc., which is a global leader in developing, manufacturing,
selling and distributing innovative diagnostic imaging agents and
products. LMI provides a broad portfolio of products, which are
primarily used for the diagnosis of cardiovascular diseases. LMI’s key
products include the echocardiography contrast agent DEFINITY®
Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite®
(Technetium Tc99m Generator), a technetium-based generator that provides
the essential medical isotope used in nuclear medicine procedures; and
Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent
used to evaluate pulmonary function and for imaging the lungs.
LMI has more than 500 employees worldwide with headquarters in North
Billerica, Massachusetts, and offices in Puerto Rico, Canada and
Australia. For more information, visit www.lantheus.com.
Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements are subject to risks and uncertainties that
may be described from time to time in our filings with the Securities
and Exchange Commission. Readers are cautioned not to place undue
reliance on the forward-looking statements contained herein, which speak
only as of the date hereof. The Company undertakes no obligation to
publicly update any forward-looking statement, whether as a result of
new information, future developments or otherwise, except as may be
required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150828005294/en/
Source: Lantheus Holdings, Inc.
Lantheus Holdings, Inc.
Investor Relations
John
Bakewell, 978-436-7073
or
Media Relations
Meara
Murphy, 978-671-8508
